Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23277094 | 1.00 | CES2 (0.39) | CES2CES1TLR8ALDH1A1ALOX15 | |
| SCHEMBL20136432 | 0.86 | CES2 (0.46) | CES2CES1ALDH1A1ALOX15LMNA | |
| SCHEMBL10332608 | 0.86 | CES2 (0.46) | CES2CES1ALDH1A1ALOX15LMNA | |
| SCHEMBL5775733 | 0.86 | CES2 (0.46) | CES2CES1ALDH1A1ALOX15LMNA | |
| SCHEMBL11893724 | 0.78 | ALDH1A1 (0.48) | CES2CES1ALDH1A1LMNATLR7 | |
| SCHEMBL5772875 | 0.78 | ALDH1A1 (0.48) | CES2CES1ALDH1A1LMNATLR7 | |
| SCHEMBL11911197 | 0.78 | ALDH1A1 (0.48) | CES2CES1ALDH1A1LMNATLR7 | |
| SCHEMBL29387927 | 0.78 | ALDH1A1 (0.48) | CES2CES1ALDH1A1LMNATLR7 | |
| SCHEMBL19900564 | 0.77 | CES2 (0.39) | CES2CES1TLR8ALDH1A1ALOX15 | |
| SCHEMBL21216773 | 0.77 | ACHE (0.41) | CES2CES1ALDH1A1ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021079962-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS | 国立大学法人大阪大学 | 2021-04-29 | — | — | WO | disclosed |
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | CES2 791/4885CES1 243/4885TLR8 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.